Medications acting on the serotonergic system for the treatment of alcohol dependent patients

Current Pharmaceutical Design

Volumn 16, Issue 19, 2010, Pages 2126-2135

  Kenna, George A ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alcohol dependence; Alcoholism; Busiprone; Fluoxetine; Ondansetron; Ritanserin; Serotonin; Sertraline; SSRI

Indexed keywords

ACAMPROSATE; BUSPIRONE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; NEFAZODONE; NORTRIPTYLINE; ONDANSETRON; PLACEBO; RITANSERIN; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MILD COGNITIVE IMPAIRMENT; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ANIMAL; DRUG EFFECTS; METABOLISM;

ALCOHOLISM; ANIMALS; HUMANS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS;

EID: 77955590219     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791516396     Document Type: Article

References (122)

1. Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 2001; 62 (supp 20): 26-31.
2. Lovinger D. Communication networks in the brain. Alcohol Health Res World, 2008; 31: 196-214.
3. Ciccocioppo R. The role of serotonin in craving: from basic research to human studies. Alcohol Alcohol 1999; 34(2): 244-53.
4. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry 1994; 36: 326-37.
5. Myers RD, Martin GE. The role of cerebral serotonin in the ethanol preference of animals. Ann NY Acad Sci 1973; 215: 135-44.
6. Lovinger D. Serotonin's role in alcohol's effects on the brain. Alcohol Health Res World 1997; 21: 114-20.
7. Casu MA, Pisu C, Lobina C, et al. Immunocytochemical study of the forebrain sorotonergic innervation in Sardinian alcoholpreferring rats. Psychopharm (Berlin) 2004; 172: 341-51.
8. McBride WJ, Bodart B, Lumeng L, et al. Association between low contents of dopamine and serotonin in the nucleus accumbens and high alcohol preference. Alcohol Clin Exp Res 1995; 19: 1420-2.
9. Li TK, McBride WJ. Pharmacogenetic models of alcoholism. Clin Neurosci 1995; 3: 182-8.
10. Agren H. Life at risk: markers of suicidality in depression. Psychiatr Dev 1983; 1: 87-103.
11. Banki CM, Molnar G. Cerebrospinal fluid 5-hydroxyindoleacetic acid as an index of central serotonergic processes. Psychiatry Res 1981; 5: 23-32.
12. Schuckit MA. Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 1996; 64: 669-76.
13. Daoust M, Chretien P, Moore N, et al. Isolation and striatal (3H) serotonin uptake: role in the voluntary intake of ethanol by rats. Pharmacol Biochem Behav 1985; 22: 205-8.
14. McBride WJ, Murphy JM, Lumeng L, et al. Serotonin and ethanol preference. Recent Dev Alcohol 1989; 7: 187-209.
15. Kranzler HR, Meyer RE. An open trial of buspirone in alcoholics. J Clin Psychopharmacol 1989; 9(5): 379-80.
16. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992; 13: 16-75.
17. Bleich S, Bonsch D, Rauh J, et al. Association of the long allele of the 5-HTTLPR polymorphism with compulsive craving in alcohol dependence. Alcohol Alcohol 2007; 42: 509-12.
18. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 1999; 281: 1318-25.
19. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am J Health Syst Pharm 2004; 61: 2380-8.
20. Johnson BA. The role of serotonergic agents as treatments for alcoholism. Drugs Today 2003; 39: 665-72.
21. Nellissery M, Feinn RS, Covault J, et al. Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. Alcohol Clin Exp Res 2003; 27: 1402-8.
22. Mason BJ, Kocsis JH, Ritvo EC, et al. A double blind, placebo controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275: 761-7.
23. Powell BJ, Campbell JL, Landon JF, et al. A double-blind, placebo- controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol Clin Exp Res 1995; 19: 462-8.
24. Hernandez-Avila CA, Modesto-Lowe V, Feinn R, et al. Nefazodone treatment of comorbid alcohol dependence and major depression. Alcohol Clin Exp Res 2004; 28: 433-40.
25. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000; 22: 493-503.
26. Roy-Byrne PP, Pages KP, Russo JE, et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000; 20: 129-36.
27. Wetzel H, Szegedi A, Scheurich A, et al. NeVeR Study Group. Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. J Clin Psychiatry 2004; 65: 1406-13.
28. Lemberger L, Rowe H, Carmichael R, et al. Pharmacologic effects in man of a specific serotonin-reuptake inhibitor. Science 1978; 199: 436-7.
29. Gulley JM, McNamara C, Barbera TJ, et al. Selective serotonin reuptake inhibitors: Effects of chronic treatment on alcoholreinforced behavior in mice. Alcohol 1995; 12: 177-181.
30. Boyce-Rustay JM, Wiedholz LM, Millstein RA, et al. Ethanolrelated behaviors in serotonin transporter knockout mice. Alcohol Clin Exp Res 2006; 30: 1957-65.
31. Pettinati HM. Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcohol Clin Exp Res 1996; 20 (7 Suppl): 23A-9.
32. Naranjo CA, Bremner KE. Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications. EXS 1994; 71: 209-19.
33. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics. A double-blind placebo controlled trial. Arch Gen Psychiatry 1997; 23: 193-203.
34. Naranjo CA, Knoke DM. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.J Clin Psychiatry 2001; 62 (Suppl 20): 18-25.
35. Fluoxetine, Micromedix, Thompson Healthcare Products, [accessed 7/23/09].
36. Naranjo CA, Kadlec KE, Sanhueza P, et al. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990; 47(4): 490-8.
37. Gerra G, Caccavari R, Delsignore R, et al. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcohol patients. Curr Therap Res 1992; 52: 291-5.
38. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16: 261-5.
39. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-7.
40. Kranzler HR, Burleson JA, Brown J, et al. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20: 1534-41.
41. Janiri L, Gobbi G, Mannelli P, et al. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 1996; 11: 109-17.
42. Kabel D, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 1996; 20: 780-4.
43. Sertraline, MicroMedix Thompson Healthcare Products [accessed 7/24/09].
44. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75: 34-56.
45. Pettinati HM, Volpicelli JR, Luck G, et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21(2): 143-53.
46. Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence. Interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000; 24: 1041-9.
47. Dundon W, Lynch KG, Pettinati HM, et al. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res 2004; 28: 1065-73.
48. Pettinati HM, Dundon W, Lipkin C. Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence. Am J Addict 2004; 13: 236-47.
49. Kranzler HR, Mueller T, Cornelius J, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006; 26: 13-20.
50. Edwards JG, Anderson I, Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507-33.
51. Tiihonen J, Ryynänen OP, Kauhanen J, et al. Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 1996; 29: 27-9.
52. Naranjo CA, Bremner KE, Lanctôt KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87-99.
53. Naranjo CA, Bremner DM, Bremner KE. Variations in response to citalopram in men and women with alcohol dependence. J Psychiatr Neuro 2000; 25: 269-75.
54. Angelone SM, Bellini L, Di Bella D, et al. Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics. Alcohol Alcohol 1998; 33: 151-6.
55. Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 2005; 78: 1-22.
56. Moak DH, Anton RF, Latham PK, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebocontrolled trial. J Clin Psychopharmacol 2003; 23: 553-62.
57. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291: 1887-96.
58. Mark TL, Kranzler HR, Poole VH, et al. Barriers to the use of medications to treat alcoholism. Am J Addict 2003; 12: 281-94.
59. Little KY, McLaughlin DP, Zhang L, et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 1998; 155: 207-13.
60. Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995; 56 (Suppl 2): 38-48.
61. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-76.
62. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15: 243-5.
63. Glennon R, Dukat M, Westkaemper RB. Serotonin receptor subtypes and ligands. In: Bloom FE, Kupfer D, Eds. Psychopharmacology: The Fourth Generation of Progress online 2000.
64. Serretti A, Artioli P, Lorenzi C, et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharm 2004; 7: 1-8.
65. Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 2004; 18: 1105-18.
66. Malec E, Malec T, Gagné MA, et al. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 1996; 20: 307-12.
67. Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 1996; 20: 853-8.
68. George DT, Rawlings R, Eckardt MJ, et al. Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol Clin Exp Res 1999; 23: 272-8.
69. Fawcett J, Kravitz HM, McGuire M, et al. Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 2000; 24: 666-74.
70. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 1994; 51: 720-31.
71. Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16(6): 1007-13.
72. Tollefson GD, Montague-Close J, Tollefson SL. Treatment of comorbid generalizes anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharm 1992; 12: 19-26.
73. Swift RM. Medications for alcohol craving. Alcohol Health Res 1999; 23: 207-13.
74. Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group. Psychopharm (Berl) 1996; 128: 206-15.
75. Wiesbeck GA, Weijers HG, Chick J, et al. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebocontrolled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999; 23: 230-5.
76. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
77. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT Gene. Science 2003; 301: 386-9.
78. Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept--an hypothesis. Alcohol Clin Exp Res 2000; 24: 1597-601.
79. Enoch MA, Goldman D. Genetics of alcoholism and substance abuse. Psychiatr Clin North Am 1999; 2: 289-99.
80. Prescott CA, Kendler KS. Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psychiatry 1999; 156: 34-40.
81. Naranjo CA, Chu AY, Tremblay LK. Neurodevelopmental liabilities in alcohol dependence: central serotonin and dopamine dysfunction. Neurotox Res 2002; 4: 343-61.
82. Heils A, Mossner R, Lesch KP. The human serotonin transporter gene polymorphism--basic research and clinical implications. J Neural Transm 1997; 104: 1005-14.
83. Lesch KP, Meyer J, Glatz K, et al. The 5-HT transporter genelinked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm 1997; 104(11-12): 1259-66.
84. Kweon YS, Lee HK, Lee CT, et al. Association of the serotonin transporter gene polymorphism with Korean male alcoholics. J Psychiatr Res 2005; 39(4): 371-6.
85. Schuckit MA, Mazzanti C, Smith TL, et al. Selective genotyping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study. Biol Psychiatry 1999; 45(5): 647-51.
86. Ishiguro H, Saito T, Akazawa S, et al. Association between drinking- related antisocial behavior and a polymorphism in the serotonin transporter gene in a Japanese population. Alcohol Clin Exp Res 1999; 23: 1281-4.
87. Greenberg BD, Tolliver TJ, Huang SJ, et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999; 88: 83-7.
88. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
89. Javors M, Tiouririne M, Prihoda T. Platelet serotonin uptake is higher in early-onset than in late-onset alcoholics. Alcohol Alcohol 2000; 35: 390-3.
90. Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995; 56 (Suppl 2): 38-48.
91. Hu X, Lipsky RH, Zhu G, et al. 5'-HTTLPR is triallelic, and the high expression allele predicts obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815.
92. Schuckit MA, Mazzanti C, Smith TL, et al. Selective genotyping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study. Biol Psychiatry 1999; 45: 647-51.
93. Hu X, Oroszi G, Chun J, et al. An expanded evaluation of the relationship of four alleles to the LR to alcohol and alcoholism risk. Alcohol Clin Exp Res 2005; 29: 8-16.
94. Schuckit MA, Smith TL, Kalmijn J. The search for genes contributing to the low level of response to alcohol: patters of findings across studies. Alcohol Clin Exp Res 2004; 28: 1449-58.
95. Branchey L, Shaw S, Lieber CS. Ethanol impairs tryptophan transport into the brain and depresses serotonin. Life Sci 1981; 29: 2751-5.
96. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry 1994; 36: 326-37.
97. Heinz A, Jones DW, Mazzanti C, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47: 643-9.
98. Little KY, McLaughlin DP, Zhang L, et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 1998; 155: 207-13.
99. Risch SC, Nemeroff CB. Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiatry 1992; 53 (Suppl): 3-7.
100. De Deurwaerdere P, Stinus L, Spampinato U. Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci 1998; 18: 6528-38.
101. Oroszi G, Goldman D. Alcoholism: genes and mechanisms. Pharmacogenomics 2004; 5: 1037-48.
102. Hammoumi S, Payen A, Favre JD, et al. Does the short variant of the serotonin transporter linked polymorphic region constitute a marker of alcohol dependence? Alcohol 1999; 17: 107-12.
103. Turker T, Sodmann R, Goebel U, et al. High ethanol tolerance in young adults is associated with the low-activity variant of the promoter of the human serotonin transporter gene. Neurosci Lett 1998; 248: 147-50.
104. Hallikainen T, Saito T, Lachman HM, et al. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. Mol Psychiatry 1999; 4: 385-8.
105. Sander T, Harms H, Lesch KP, et al. Association analysis of a regulatory variation of the serotonin transporter gene with severe alcohol dependence. Alcohol Clin Exp Res 1997; 21: 1356-9.
106. Sander T, Harms H, Dufeu P, et al. Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder. Biol Psychiatry 1998; 43: 908-12.
107. Herman AI, Philbeck JW, Vasilopoulos NL, et al. Serotonin transporter promoter polymorphism and differences in alcohol consumption behaviour in a college student population. Alcohol Alcohol 2003; 38: 446-9.
108. Matsushita S, Yoshino A, Murayama M, et al. Association study of serotonin transporter gene regulatory region polymorphism and alcoholism. Am J Med Genet 2001; 105: 446-50.
109. Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997; 101: 243-6.
110. Edenberg HJ, Reynolds J, Koller DL, et al. A family-based analysis of whether the functional promoter alleles of the serotonin transporter gene HTT affect the risk for alcohol dependence. Alcohol Clin Exp Res 1998; 22: 1080-5.
111. Johnson BA, Ait-Dowd, N. Neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Psychopharm 2000; 149: 327-44.
112. Johnson BA, Roache J, Ait-Daoud N, et al. Ondansetron for reduction of drinking among biologically predisposed patients: a randomized controlled trial. JAMA 2000; 284: 963-71.
113. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992; 13: 16-75.
114. Johnson BA, Roache JD, Ait-Daoud N, et al. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl) 2002; 160: 408-13.
115. Kranzler HR, Pierucci-Lagha A, Feinn R, et al. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, openlabel study. Alcohol Clin Exp Res 2003; 27: 1150-5.
116. Ait-Daoud N, Roache JD, Dawes MA, et al. Can serotonin transporter genotype predict craving in alcoholism? Alcohol Clin Exp Res 2009; 32: 209-16.
117. Kenna GA, Zywiak WH, McGeary JE, et al. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcoholdependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 2009; 33(2): 315-23.
118. Kenna GA. Pharmacogenomics and the future of alcohol dependence treatment research on the neurobiology of alcohol use disorders. In: Sher L, Ed. NY: Nova Publishers 2008; vol. 6: pp. 79- 112.
119. Leggio L, Kenna GA, Fenton M, et al. Typologies of alcohol dependence: from jellinek to genetics and beyond. Neuropsychol Rev 2009; 19: 115-29.
120. Christmas D, Hood S, Nutt D. Potential novel anxiolytic drugs. Curr Pharm Des. 2008; 14(33): 3534-46.
121. McCreary AC, Jones CA. Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism. Curr Pharm Des. 2010; 16(5): 516-21.
122. Wang LL, Yang AK, He SM, et al. Identification of molecular targets associated with ethanol toxicity and implications in drug development. Curr Pharm Des. 2010; 16(11): 1315-55.